Camlin Fine Sciences Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Guidance held despite a 20% shipment hit: Middle East conflict delayed shipments, raised freight costs and stretched working capital cycles, yet management reaffirmed its full FY27 top-line and margin guidance.
• Vanillin realizations are turning: Average realization improved from sub-\$11 to over \$12.5 in Q4, and the blended FY27 expectation is \$13.5–\$14, helped by tariff withdrawal and Syensqo’s expected price move to \$19–\$20.
• The Blends engine is scaling: The global Blends business crossed ₹100 crores in the first month of FY27, and the full-year target is upwards of ₹1,400 crores, though Vinpai’s liquidity crunch made it miss near-term projections.
• Cash flow, not demand, is the binding constraint: A large order book exists across all businesses, but longer working capital cycles, high freight costs and logistics unpredictability are the real limits on growth.
• What to watch next quarter: Whether the U.S. and Europe vanillin volume pickup materializes as guided, whether Vinpai’s liquidity fix sticks, and how quickly the diphenol import substitution flows through to margins.

Vanillin & Aroma: The Pricing Turn

• Realization recovery underway: Average vanillin realization moved from sub-\$11 to more than \$12.5 in Q4 as channel stock was liquidated; the blended FY27 expectation is \$13.5–\$14, supported by the withdrawal of tariffs now at 15% in the U.S. and Europe.
• Ethyl vanillin campaign launched: Methyl vanillin production stopped on January 15; the plant was modified over two months to run an ethyl vanillin campaign of ~600 metric tons, with orders on hand for Q1 of ~300 metric tons. Some methyl vanillin channel stock is still being carried for sale in subsequent quarters.
• Syensqo’s pricing floor helps Camlin: Syensqo is pricing at \$17–\$18 to saturate the market and push Chinese competitors out; Camlin cannot price higher than Syensqo and is maintaining pricing alongside them. Management expects Syensqo to raise prices to \$19–\$20 in the next couple of months as its capacity utilization reaches 100%.
• U.S. volume recovery expected: Q1 will show some pickup in the U.S., and total combined U.S. and Europe volumes in Q1 will grow over Q4 of FY26, then keep picking up toward the FY27 estimate of 2,200–2,400 metric tons.
• European market is tighter: Methyl vanillin has no stocks available to send to Europe until the next campaign starts, so the market situation there is much better.
• Cost base has moved up post-war: The pre-war cost assumption of \$9–\$9.5 per kg is no longer valid; raw material costs have risen, with phenol costs up, glycolic acid and caustic higher, and caustic doubling in value after the war. Management pegged current components at roughly \$7.5 RMC (up by \$1.20) plus \$1.5 conversion, totaling around \$10.5.

Momaya: "Syensqo is trying to saturate the market. I mean, get the Chinese out of the market completely. And they've taken this position of pricing, and we can't price higher than them."

Blends & Acquisitions: Scaling with Friction

• Blends business hit a new monthly high: The global Blends business clocked more than ₹100 crores in the first month of FY27, and the full-year target is upwards of ₹1,400 crores. The company has invested in human capital over the last two years to build pole position for higher growth.
• Vinpai missed near-term projections: Vinpai was expected to deliver ₹10 crores in its first month but achieved only ~₹17 crores over the last three months combined, due to working capital cycles and a liquidity crunch. Management is confident it will deliver results as previously discussed once liquidity issues are addressed.
• Vinpai and Vitafor approaching breakeven: Vitafor posted EBITDA of ₹1.6 crores for the full year; Vinpai is at a similar ₹1.4–₹1.6 crores level, with both expected to be above breakeven EBITDA in FY27.
• Straights strategy shifted: The Straights business held market share but revenue reduced due to local competition and pricing pressure. Management is now using more Straights internally to make Blends rather than competing with local Indian players, so some Straights sales have moved into the Blends business.
• Vinpai added debt to the consolidated book: Vinpai brought ~₹60 crores of existing loans onto the balance sheet and recorded an EBITDA loss of ₹10 crores due to liquidity issues. The open offer required ₹30 crores, which was borrowed at year-end and placed in escrow.

Supply Chain & Geopolitical Drag

• Shipments took a 20% hit in Q4: Sales were impacted by around 20% due to delayed shipments, lack of ships and increased freight time across global markets. The conflict also affected raw material availability and prices.
• Freight costs have nearly tripled on key lanes: Freight costs to the American continent are almost three times pre-war levels, and 20-day shipments are now taking 40–50 days. Management expects logistics uncertainty to persist even if the war stops, with at least a quarter needed to return to normal.
• Working capital cycle stretched: Longer delivery times have directly impacted the working capital cycle, which in turn constrained business growth in some geographies. Management flagged this as a bigger challenge than the market itself.

Parab: "I don't think even if tomorrow, the war stops, this thing is going to get unwound in a day or a week. We feel that this will linger on for some time, at least it will take a quarter to come back to the normal situation."

Diphenol & Performance Chemicals: Shutting a Cash Burn

• Diphenol manufacturing discontinued: The diphenol plant was shut down as a conscious decision to reduce cash burn from high and inconsistent raw material prices, with phenol moving from ₹85 to ₹150 per kg and lower Catechol realizations. Manufacturing continued until May 22, then stopped; the full impact of importing instead will show in Q2.
• Hydroquinone secured from China: The company has already secured Hydroquinone from Chinese manufacturers at a reasonable rate for the next quarter and will import rather than manufacture.
• Catechol inventory sufficient for 8–9 months: Existing Catechol stock of 3,000 tons covers 8–9 months of vanillin production, and the company will not import more. Catechol represents only about a quarter of raw material needs.
• Performance chemicals to become minimal: After stopping diphenol production, performance chemicals will be a very small part of the business, and management’s focus is not on that segment. The plant will be evaluated for repurposing based on raw material prices, competition, Chinese response and the conflict situation.

Balance Sheet & Capital

• Debt rose modestly to ~₹670 crores: The increase from ~₹620 crores was only ₹50 crores net, because an ₹85 crore Italian loan was knocked out by the CFS Europe liquidation, offset by ₹45 crores working capital debt in India, ₹30 crores for the Vinpai open offer, and ~₹60 crores from Vinpai’s existing loans.
• CFS Europe liquidation closed the cash burn: The liquidation was completed, a gain on loss of control of ~₹100-odd crores was booked, and the cash burn of ~₹50–₹60 crores per year from discontinued operations will go to zero from next quarter.
• Overall debt repayment is manageable: Total repayment for the year is ~₹60–₹70 crores, which management says can be managed. If turnover increases faster, additional liquidity will be needed, and the company is looking at market support on debt for growth and to hold cash for the conflict situation.
• Equity infusion is a last resort: Authorized capital was increased in March to keep the equity infusion door open, but management stated it is not on the table at all. The preference is a combination of structured debt in India and bank debt in Mexico, with cost assessed by the lender and kept as minimal as possible at market rates.
• Tariff refund of ₹9 crores lodged: After the Supreme Court order withdrawing the tariff, a duty claim of ₹9 crores paid through customs until February was applied for and accepted by authorities. Historically, refunds have been 50% cash and 50% adjusted against duty, though the U.S. government is now indicating cash upfront may be possible.

Costs & Margins

• Employee costs rose on Blends investment and Vinpai consolidation: Employee cost increased due to two years of investment in human capital for Blends growth, plus Vinpai being added for a full quarter versus one month in the prior quarter. No significant changes are expected going forward.
• Gross margins expected to hold at ~48%: Management expects to maintain ~48% gross margins, with a possible 1% swing up or down, though the shift from manufacturing diphenol to importing was not directly addressed as a margin risk.
• TBHQ and BHA pricing improving: Cost increases are being passed on with a lag; TBHQ prices have corrected upward and BHA pricing is slightly better than pre-war. Gaining market share in the blends business is providing economies of scale in TBHQ and BHA production.
• Freight costs remain the wildcard: Freight costs have increased over the last six months and will remain high even if the war ends; unwinding will take at least a quarter. Overall costs are described as under control except for freight.

Momaya: "Our bigger challenge is, of course, the longer working capital cycles and logistics and cash flow. So that's what we need to address because we have a large order book even in our -- all our businesses actually and executing that with tight cash flow position is a bigger challenge than the market itself."

Guidance & Commitments

Key Metrics